{"id":34824,"date":"2025-06-23T11:00:00","date_gmt":"2025-06-23T09:00:00","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=34824"},"modified":"2025-07-17T17:24:36","modified_gmt":"2025-07-17T15:24:36","slug":"experts-corner-adcs-adcs-bispecific-2","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/","title":{"rendered":"Experts&#8217; corner : ADCs\/ADCs Bispecific"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"34824\" class=\"elementor elementor-34824 elementor-34121\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-70ba9a4 e-flex e-con-boxed e-con e-parent\" data-id=\"70ba9a4\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-21ac03f elementor-widget elementor-widget-text-editor\" data-id=\"21ac03f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>With &#8220;The Experts Corner,&#8221; MabDesign offers a deep dive into the heart of innovation in biotherapies. Through exclusive interviews with industry experts, discover their market vision, their analyses of current challenges, and their perspectives on the latest advances. These inspiring conversations will help you better understand the present and future of biomanufacturing and <span data-teams=\"true\">biopharmaceuticals<\/span>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bb69397 e-flex e-con-boxed e-con e-parent\" data-id=\"bb69397\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-0f10725 e-con-full e-flex e-con e-child\" data-id=\"0f10725\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6ba549e elementor-widget__width-initial elementor-widget elementor-widget-image\" data-id=\"6ba549e\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"491\" height=\"513\" src=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Alain-Beck-Copie.jpg\" class=\"attachment-large size-large wp-image-34127\" alt=\"\" srcset=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Alain-Beck-Copie.jpg 491w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Alain-Beck-Copie-287x300.jpg 287w\" sizes=\"(max-width: 491px) 100vw, 491px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1285290 e-con-full e-flex e-con e-child\" data-id=\"1285290\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c1f29b9 elementor-widget elementor-widget-heading\" data-id=\"c1f29b9\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">ADCs and their bispecific formats<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-185c31b e-con-full e-flex e-con e-child\" data-id=\"185c31b\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ff9880c elementor-widget elementor-widget-heading\" data-id=\"ff9880c\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Alain Beck<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-95226ce elementor-widget elementor-widget-heading\" data-id=\"95226ce\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h5 class=\"elementor-heading-title elementor-size-default\">CMC Director at Laboratoires Pierre Fabre<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bbd1a3a e-con-full e-flex e-con e-child\" data-id=\"bbd1a3a\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-431b3cd elementor-view-default elementor-widget elementor-widget-icon\" data-id=\"431b3cd\" data-element_type=\"widget\" data-widget_type=\"icon.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-wrapper\">\n\t\t\t<div class=\"elementor-icon\">\n\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-quote-left\" viewBox=\"0 0 512 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M464 256h-80v-64c0-35.3 28.7-64 64-64h8c13.3 0 24-10.7 24-24V56c0-13.3-10.7-24-24-24h-8c-88.4 0-160 71.6-160 160v240c0 26.5 21.5 48 48 48h128c26.5 0 48-21.5 48-48V304c0-26.5-21.5-48-48-48zm-288 0H96v-64c0-35.3 28.7-64 64-64h8c13.3 0 24-10.7 24-24V56c0-13.3-10.7-24-24-24h-8C71.6 32 0 103.6 0 192v240c0 26.5 21.5 48 48 48h128c26.5 0 48-21.5 48-48V304c0-26.5-21.5-48-48-48z\"><\/path><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3dd7198 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"3dd7198\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Antibody-drug conjugates have been among the most dynamic classes of anti-cancer therapies over the past five years.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b4eba7b elementor-widget__width-initial elementor-view-default elementor-widget elementor-widget-icon\" data-id=\"b4eba7b\" data-element_type=\"widget\" data-widget_type=\"icon.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-wrapper\">\n\t\t\t<div class=\"elementor-icon\">\n\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-quote-right\" viewBox=\"0 0 512 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M464 32H336c-26.5 0-48 21.5-48 48v128c0 26.5 21.5 48 48 48h80v64c0 35.3-28.7 64-64 64h-8c-13.3 0-24 10.7-24 24v48c0 13.3 10.7 24 24 24h8c88.4 0 160-71.6 160-160V80c0-26.5-21.5-48-48-48zm-288 0H48C21.5 32 0 53.5 0 80v128c0 26.5 21.5 48 48 48h80v64c0 35.3-28.7 64-64 64h-8c-13.3 0-24 10.7-24 24v48c0 13.3 10.7 24 24 24h8c88.4 0 160-71.6 160-160V80c0-26.5-21.5-48-48-48z\"><\/path><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-34244d1 e-flex e-con-boxed e-con e-parent\" data-id=\"34244d1\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-e6b8003 e-con-full e-flex e-con e-child\" data-id=\"e6b8003\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e2e2618 elementor-widget__width-initial elementor-widget elementor-widget-image\" data-id=\"e2e2618\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"800\" height=\"465\" src=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/PIERRE_FABRE_LOGOTYPE_RVB-1024x595.png\" class=\"attachment-large size-large wp-image-34125\" alt=\"\" srcset=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/PIERRE_FABRE_LOGOTYPE_RVB-1024x595.png 1024w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/PIERRE_FABRE_LOGOTYPE_RVB-300x174.png 300w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/PIERRE_FABRE_LOGOTYPE_RVB-768x446.png 768w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/PIERRE_FABRE_LOGOTYPE_RVB-1536x892.png 1536w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/PIERRE_FABRE_LOGOTYPE_RVB-2048x1190.png 2048w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7ffca97 e-con-full e-flex e-con e-child\" data-id=\"7ffca97\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-256af04 elementor-widget elementor-widget-text-editor\" data-id=\"256af04\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Pierre Fabre Laboratories is one of Europe\u2019s leading pharmaceutical companies. For over 40 years, we have established ourselves as a global player in oncology, with full control of the value chain\u2014from research and development to commercialization. Our oncology portfolio includes treatments for colorectal, breast, lung, and skin cancers, as well as certain hematologic malignancies and precancerous skin conditions such as actinic keratosis.<\/p><p>The company employs more than 10,200 people worldwide. In 2024, our R&amp;D budget reached \u20ac220 million, with around 70% allocated to targeted cancer therapies and the remaining 30% to dermatology and skincare. Headquartered in France\u2019s Occitanie region and operating in 120 countries, over 90% of our products are manufactured in France.<\/p><p>The majority shareholder of Pierre Fabre Laboratories\u2014holding 86% of the capital\u2014is the Pierre Fabre Foundation, a public-interest organization. This unique governance model ensures the company\u2019s independence and long-term vision. Dividends paid to the Foundation fund humanitarian programs that improve access to healthcare in developing countries.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0fec223 e-flex e-con-boxed e-con e-parent\" data-id=\"0fec223\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2c0b365 elementor-widget elementor-widget-text-editor\" data-id=\"2c0b365\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>What are your current roles and responsibilities within the company?<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b242629 elementor-widget elementor-widget-text-editor\" data-id=\"b242629\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>I serve as the Director of Chemistry, Manufacturing, and Controls (CMC) for biological molecules such as monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and Fc-fusion proteins. My responsibilities include leading the CMC strategy across various projects, working closely with multidisciplinary R&amp;D teams as well as external partners, including Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b41be0d e-flex e-con-boxed e-con e-parent\" data-id=\"b41be0d\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-81de370 elementor-widget elementor-widget-text-editor\" data-id=\"81de370\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>With over 100 bispecific ADCs currently in development, including two candidates at Phase III (source: GlobalData), what is your perspective on the dynamics and future of this market?<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2460c79 e-flex e-con-boxed e-con e-parent\" data-id=\"2460c79\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-587cae2 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"587cae2\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>&#8220;In parallel, bi- and multi-specific antibodies have also shown strong momentum, both in oncology and in other therapeutic areas&#8221;.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e9eac3b elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e9eac3b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Traditional antibody-drug conjugates (ADCs)\u2014which consist of a canonical antibody chemically linked to a cytotoxic payload via a linker\u2014have been among the most dynamic classes of anti-cancer therapies over the past five years. This is reflected in the steadily growing number of marketing authorizations (currently 16, including 4 approvals in the past six months), as well as in the many acquisitions and high-profile deals that have occurred in the field over the past three years.<\/p><p><strong>In parallel, bi- and multi-specific antibodies (BsAbs and MsAbs) have also shown strong momentum, both in oncology and in other therapeutic areas.<\/strong> Bispecific ADCs (BsADCs) sit at the intersection of these two approaches, offering the potential for improved efficacy beyond what either traditional ADCs or BsAbs can achieve alone. Among the most advanced candidates in clinical development are anbanitumab repodotecan (JSKN003, a HER2 x HER2 biparatopic ADC from Jiangsu Alphamab, currently at Phase III for ovarian cancer) and BL-B01D1 (an EGFR x HER3 BsADC with a topoisomerase inhibitor payload from Baili, in development for non-small cell lung cancer).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ad30eb0 e-flex e-con-boxed e-con e-parent\" data-id=\"ad30eb0\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-505aec2 elementor-widget elementor-widget-text-editor\" data-id=\"505aec2\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>Could you share some examples of recent collaborations in the field of New Biological Entities at Pierre Fabre?<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0e4dd0a e-flex e-con-boxed e-con e-parent\" data-id=\"0e4dd0a\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8ec2c1a elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"8ec2c1a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>&#8220;The anti-c-Met antibody telisotuzumab was originally discovered and optimized in Pierre Fabre\u2019s laboratories and licensed to Abbott in 2010&#8221;.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5636996 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"5636996\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>On March 12, 2025, Pierre Fabre Laboratories and RedRidge Biologics (based in Basel) announced an exclusive R&amp;D collaboration and licensing agreement aimed at identifying and developing biparatopic antibody-based drug candidates targeting multiple antigens.<\/p><p>Another notable example is telisotuzumab vedotin (Emrelis), an ADC that received accelerated approval from the FDA on May 14, 2025, for the treatment of adults with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) characterized by high c-Met protein overexpression. <strong>The anti-c-Met antibody telisotuzumab (ABT-700, hz224G11) was originally discovered and optimized in Pierre Fabre\u2019s laboratories and licensed to Abbott in 2010<\/strong> (Gonzalez A et al., <em>Int. J. Cancer<\/em>, 2016).This antibody was initially evaluated in Phase I as a naked antibody (ABT-400), and later as two ADCs\u2014telisotuzumab vedotin (FDA-approved for NSCLC) and telisotuzumab adizutecan (Topoisomerase I inhibitor payload, currently in Phase III for colorectal cancer). It has also been developed into a trispecific antibody (ABBV-303), which engages both NK cells and CD8+ T cells against c-Met-expressing tumors (currently in Phase I for solid tumors). This stands as a successful example of licensing-out from Pierre Fabre\u2019s early-stage innovation.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-d50c4c4 e-flex e-con-boxed e-con e-parent\" data-id=\"d50c4c4\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ba90dca elementor-widget elementor-widget-heading\" data-id=\"ba90dca\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Innovations, challenges and perspectives of ADCs\/Bispecific ADCs <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f21294f e-flex e-con-boxed e-con e-parent\" data-id=\"f21294f\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5a0dedf elementor-widget elementor-widget-text-editor\" data-id=\"5a0dedf\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>Could you explain the growing interest in BpAbs, BpADCs, and BsADCs? Why do these types of biologics hold such promising clinical potential?<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-737d771 e-con-full e-flex e-con e-parent\" data-id=\"737d771\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6635ec1 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"6635ec1\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>&#8220;A first clinical proof of concept was provided by the FDA&#8217;s accelerated marketing authorization in 2024&#8230;&#8221;.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-77a721a elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"77a721a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Biparatopic antibodies (BpAbs) are multispecific therapeutic proteins that target two distinct epitopes on the same antigen. This design offers several advantages over conventional monoclonal antibodies, including enhanced functional antagonism, improved internalization, and tailored agonistic effects. These features can translate into more potent and selective therapeutic action.<\/p><p><strong>A key clinical proof of concept came in 2024 with the FDA\u2019s accelerated approval of zanidatamab<\/strong> (Ziihera), a HER2 x HER2 biparatopic antibody, for the treatment of HER2-positive biliary tract cancer. As previously mentioned, JSKN003 (a HER2 x HER2 BpADC) and BL-B01D1 (an EGFR x HER3 BsADC) have both recently entered Phase III trials, further illustrating the clinical momentum and therapeutic promise of this new generation of targeted biologics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-09f6ba3 e-flex e-con-boxed e-con e-parent\" data-id=\"09f6ba3\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ca5ab23 elementor-widget elementor-widget-text-editor\" data-id=\"ca5ab23\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>What are the main challenges and hurdles in developing bispecific ADCs?<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bcad6c6 e-flex e-con-boxed e-con e-parent\" data-id=\"bcad6c6\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-30a5e5f elementor-widget elementor-widget-text-editor\" data-id=\"30a5e5f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Both ADCs and bispecific antibodies are significantly more complex molecular entities compared to traditional monoclonal antibodies. This added complexity impacts multiple aspects of their development\u2014including molecular design, optimization for developability, and pharmaceutical development, particularly from a Chemistry, Manufacturing, and Controls (CMC) standpoint.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-9cae32b e-flex e-con-boxed e-con e-parent\" data-id=\"9cae32b\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ebb93bb elementor-widget elementor-widget-text-editor\" data-id=\"ebb93bb\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>Is the production of these therapies more complex compared to monospecific ADCs?<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-3fe0c98 e-flex e-con-boxed e-con e-parent\" data-id=\"3fe0c98\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-448be96 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"448be96\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>&#8220;Not all bispecific formats are suitable for ADC development, which adds an additional layer of selectivity in the design phase&#8221;.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cab5050 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"cab5050\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong><em>\u201cNot all bispecific formats are suitable for ADC development, which adds an additional layer of difficulties in the design phase\u201d.<\/em><\/strong><\/p><p>Absolutely. The complexity of each component class\u2014ADCs and bispecific antibodies\u2014adds up, making bispecific ADCs particularly challenging to design and produce<strong>. Not all bispecific formats are suitable for ADC development, which adds an additional layer of <em>difficulties<\/em> in the design phase.<\/strong><\/p><p>Early access to highly sensitive analytical techniques is critical. Native mass spectrometry, combined with various chromatographic and electrophoretic separation methods, is essential to confirm the theoretical structure of these molecules and to guide optimization, including forced degradation studies.<\/p><p>These analytical strategies are key to advancing the developability of bispecific ADCs, and I will be presenting our latest findings on this topic at several upcoming conferences: WADC Asia in Seoul and at the FDA in June, the 35th International Symposium on Pharmaceutical and Biomedical Analysis in Shanghai in July, and at MabDesign\u2019s Bioproduction Congress 2025 event in September.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f4d5861 e-flex e-con-boxed e-con e-parent\" data-id=\"f4d5861\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3bbbce7 elementor-widget elementor-widget-text-editor\" data-id=\"3bbbce7\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>You presented the strategies and challenges of this field at AIS last June (AIS 2024, Montpellier, organized by LabEx MabImprove and MabDesign). Do you believe that upcoming innovations will help address these challenges in the near future?<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0c249e0 e-con-full e-flex e-con e-child\" data-id=\"0c249e0\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6bbe636 elementor-widget elementor-widget-text-editor\" data-id=\"6bbe636\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>At AIS 2024 and more recently at WADC London 2025, I had the opportunity to present the latest advances in the design, characterization, and early clinical development of the first biparatopic and bispecific ADCs. These innovative formats also received significant attention at the AACR Annual Meeting in Chicago this past April.<\/p><p>There is clearly strong momentum in the field. However, while preclinical data and early-phase clinical results (Phases I and II) are encouraging, it will be essential to confirm these findings through robust Phase III trials involving larger patient cohorts. Only then will we fully understand the clinical value and therapeutic potential of these next-generation biologics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-227807b e-flex e-con-boxed e-con e-parent\" data-id=\"227807b\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-872be66 elementor-widget elementor-widget-text-editor\" data-id=\"872be66\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>What are your expectations for the session you will be chairing at AIS 2025 organized by MabDesign?<\/strong><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-d7b526a e-flex e-con-boxed e-con e-parent\" data-id=\"d7b526a\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b9cab30 elementor-widget elementor-widget-text-editor\" data-id=\"b9cab30\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>For AIS 2025, I will be chairing a session dedicated to the Fc domain of antibodies, including bispecifics, ADCs, and Fc-fusion proteins. The choice between Fc-competent, Fc-silent, or Fc-enhanced formats is a strategic one, with significant implications for pharmacology, toxicity, half-life, product differentiation, intellectual property, and regulatory considerations.<\/p><p>I\u2019m looking forward to in-depth scientific discussions and experience sharing during this session, which I believe will be both informative and intellectually stimulating.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-c7d7e09 e-flex e-con-boxed e-con e-parent\" data-id=\"c7d7e09\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ef3f597 elementor-widget elementor-widget-heading\" data-id=\"ef3f597\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h6 class=\"elementor-heading-title elementor-size-default\">Alain Beck, Laboratoires Pierre Fabre, interviewed by the MabDesign team - May 2025<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-9183fdc e-flex e-con-boxed e-con e-parent\" data-id=\"9183fdc\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-d8da45e e-con-full e-flex e-con e-child\" data-id=\"d8da45e\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-0c5e97c elementor-widget elementor-widget-heading\" data-id=\"0c5e97c\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">DO YOU WANT TO KNOW MORE?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ab2242f e-flex e-con-boxed e-con e-child\" data-id=\"ab2242f\" data-element_type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4ef0cfd elementor-widget__width-initial elementor-widget elementor-widget-image\" data-id=\"4ef0cfd\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"731\" height=\"341\" src=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Logo-AIS-sans-fond.png\" class=\"attachment-large size-large wp-image-34129\" alt=\"\" srcset=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Logo-AIS-sans-fond.png 731w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Logo-AIS-sans-fond-300x140.png 300w\" sizes=\"(max-width: 731px) 100vw, 731px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d327606 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d327606\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Don&#8217;t miss the thirteenth edition of the <a href=\"https:\/\/aiscongress.com\/\" target=\"_blank\" rel=\"noopener\">Antibody Industrial Symposium<\/a>, organized by MabDesign in collaboration with Labex MabImprove, which will take place on <strong>June 25 and 26, 2025 in Tours<\/strong>.<\/p><p><i>You can already <a href=\"https:\/\/aiscongress.com\/register-b2b-access\/\" target=\"_blank\" rel=\"noopener\">register <\/a><\/i><i>or <a href=\"ana-sofia.antunes@mabdesign.fr\" target=\"_blank\" rel=\"noopener\">contact us<\/a> for more information !<\/i><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-73e803d elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"73e803d\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"MsoNormal\" style=\"text-align: justify;\">MabDesign has acquired and cultivated expertise in all areas associated with biomedicines and biomanufacturing. <a href=\"https:\/\/mabdesign.fr\/en\/the-team\/\">Our team<\/a> is at your disposal to support you in all your projects related to the biotherapies sector, and in particular cell-based therapies. Feel free to explore <a href=\"https:\/\/mabdesign.fr\/en\/our-consulting-offer-biomedicaments-bioproduction\/\">our range of services<\/a>, <a href=\"https:\/\/mabdesign-formation.fr\/\">training courses<\/a> and <a href=\"https:\/\/mabdesign.fr\/en\/our-events\/\">events<\/a> if you&#8217;d like to find out more!<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a5f4fc0 elementor-align-center elementor-widget__width-initial elementor-widget elementor-widget-button\" data-id=\"a5f4fc0\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"mailto:services@mabdesign.fr?subject=Offre%20de%20services%20\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Contact us<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>The Experts Corner &#8211; Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs.<\/p>\n","protected":false},"author":6,"featured_media":34433,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[88,196],"tags":[136,99,359],"class_list":["post-34824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bio-hub-en","category-interview-en","tag-adc-en","tag-antibodies","tag-bispecific"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Experts&#039; corner : ADCs\/ADCs Bispecific - MabDesign<\/title>\n<meta name=\"description\" content=\"The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs. The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Experts&#039; corner : ADCs\/ADCs Bispecific - MabDesign\" \/>\n<meta property=\"og:description\" content=\"The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs. The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-17T15:24:36+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"2048\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Maissa Pote\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maissa Pote\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/\"},\"author\":{\"name\":\"Maissa Pote\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\"},\"headline\":\"Experts&#8217; corner : ADCs\/ADCs Bispecific\",\"datePublished\":\"2025-06-23T09:00:00+00:00\",\"dateModified\":\"2025-07-17T15:24:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/\"},\"wordCount\":1506,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg\",\"keywords\":[\"ADC\",\"antibodies\",\"bispecific\"],\"articleSection\":[\"Bio-hub\",\"Interview\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/\",\"name\":\"Experts' corner : ADCs\/ADCs Bispecific - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg\",\"datePublished\":\"2025-06-23T09:00:00+00:00\",\"dateModified\":\"2025-07-17T15:24:36+00:00\",\"description\":\"The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs. The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg\",\"width\":2560,\"height\":2048},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Experts&rsquo; corner : ADCs\/ADCs Bispecific\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\",\"name\":\"Maissa Pote\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"caption\":\"Maissa Pote\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/communication\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Experts' corner : ADCs\/ADCs Bispecific - MabDesign","description":"The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs. The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/","og_locale":"en_US","og_type":"article","og_title":"Experts' corner : ADCs\/ADCs Bispecific - MabDesign","og_description":"The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs. The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs.","og_url":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/","og_site_name":"MabDesign","article_published_time":"2025-06-23T09:00:00+00:00","article_modified_time":"2025-07-17T15:24:36+00:00","og_image":[{"width":2560,"height":2048,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg","type":"image\/jpeg"}],"author":"Maissa Pote","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Maissa Pote","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/"},"author":{"name":"Maissa Pote","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029"},"headline":"Experts&#8217; corner : ADCs\/ADCs Bispecific","datePublished":"2025-06-23T09:00:00+00:00","dateModified":"2025-07-17T15:24:36+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/"},"wordCount":1506,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg","keywords":["ADC","antibodies","bispecific"],"articleSection":["Bio-hub","Interview"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/","url":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/","name":"Experts' corner : ADCs\/ADCs Bispecific - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg","datePublished":"2025-06-23T09:00:00+00:00","dateModified":"2025-07-17T15:24:36+00:00","description":"The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs. The Experts Corner - Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs\/Bispecific ADCs.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/Interview-Alain-Beck-ENG-scaled.jpg","width":2560,"height":2048},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/experts-corner-adcs-adcs-bispecific-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Experts&rsquo; corner : ADCs\/ADCs Bispecific"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029","name":"Maissa Pote","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","caption":"Maissa Pote"},"url":"https:\/\/mabdesign.fr\/en\/author\/communication\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/34824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=34824"}],"version-history":[{"count":11,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/34824\/revisions"}],"predecessor-version":[{"id":34836,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/34824\/revisions\/34836"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/34433"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=34824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=34824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=34824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}